Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment

Oncology Letters

Volumn 3, Issue 6, 2012, Pages 1288-1292

  Lu, Hong Yang ^a   Mao, Wei Min ^a   Cheng, Qiao Yuan ^b   Chen, Bo ^a   Cai, Ju Fen ^a   Wang, Xiao Jia ^a   Wang, Zeng ^a   Xie, Fa Jun ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b Zhejiang Institute for Food and Drug Control   (China)

Author keywords

Combined small cell lung cancer; Epidermal growth factor receptor; Gene mutation; Pyrosequencing assay technology

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; IRINOTECAN; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHINA; CLINICAL ARTICLE; EXON; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG RESECTION; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; PYROSEQUENCING; RETROSPECTIVE STUDY; SMOKING; SURVIVAL TIME;

EID: 84859455544     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.666     Document Type: Article

References (21)

1. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
2. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
3. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
4. Rosell R, Gervais R, Vergnenegre A, et al: Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 29 (Suppl): abs. 7503, 2011.
5. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742, 2011.
6. Douillard JY, Shepherd FA, Hirsh V, et al: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28: 744-752, 2010.
7. Okamoto I, Araki J, Suto R, et al: EGFR mutation in gefitinib responsive small-cell lung cancer. Ann Oncol 17: 1028-1029, 2006.
8. Zakowski MF, Ladanyi M, Kris MG, et al: EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355: 213-215, 2006.
9. Qian J, Qin S, Tang Q, et al: Gefitinib in patients with advanced refractory small cell lung cancer contemporaneous with superior venacava syndrome. Chin Clin Oncol 10: 243-244, 2005.
10. Lu HY, Sun WY, Chen B, et al: Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China. Neoplasma 59: 100-104, 2012.
11. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24: 4539-4544, 2006.
12. Mangum MD, Greco FA, Hainsworth JD, et al: Combined small-cell and non-small-cell lung cancer. J Clin Oncol 7: 607-612, 1989.
13. Fraire AE, Johnson EH, Yesner R, et al: Prognostic significance of histopathologic subtype and stage in small cell lung cancer. Hum Pathol 23: 520-528, 1992.
14. Nicholson SA, Beasley MB, Brambilla E, et al: Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 26: 1184-1197, 2002.
15. Tatematsu A, Shimizu J, Murakami Y, et al: Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 14: 6093-6096, 2008.
16. Shiao TH, Chang YL, Yu CJ, et al: Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J Thorac Oncol 5: 195-198, 2011.
17. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.
18. Wu YL, Zhong WZ, Li LY, et al: Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2: 430-439, 2007.
19. Fukui T, Tsuta K, Furuta K, et al: Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci 98: 1714-1719, 2007.
20. Dahabreh IJ, Linardou H, Siannis F, et al: Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 16: 291-303, 2010.
21. Rostad H, Naalsund A, Jacobsen R, et al: Small cell lung cancer in Norway. Should more patients have offered surgical therapy? Eur J Cardiothorac Surg 26: 782-786, 2004.